Humanigen Inc
533 Airport Drive, Suite 400
Burlingame
CA
94010
United States
Tel: 650-218-0606
Website: http://www.humanigen.com/
76 articles about Humanigen Inc
-
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
5/28/2021
Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced that the company submitted an application to the US Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for lenzilumab for the treatment of patients hospitalized with COVID-19.
-
GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021
5/26/2021
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that granulocyte macrophage-colony stimulating factor (GM-CSF) gene-edited CAR-T data will be presented at the International Society for Cell & Gene Therapy (ISCT) 2021 Annual Meeting
-
Humanigen to Present at Jefferies Healthcare Conference
5/19/2021
Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Company’s management team will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 1-4, 2021.
-
COVID-19 News: Test for Asymptomatic People, Bemcentinib in Hospitalized COVID-19 Patients and More
5/18/2021
Please check out the biopharma industry's COVID-19 stories that are trending for May 18, 2021. -
Humanigen Reports Third Quarter and Nine Months Ended September 30, 2020 Financial Results
11/11/2020
-Underwritten Public Offering and Nasdaq Listing Completed in September 2020 -Positive Phase 3 Interim Analysis Reported with an Estimated 37 percent More Recoveries Observed in the Lenzilumab Arm Versus Current Standard of Care
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
-
Clinical Catch-Up: November 2-6
11/9/2020
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look. -
Humanigen Announces Positive Interim Phase 3 Data of Lenzilumab™ in Patients Hospitalized with COVID-19
11/6/2020
Interim data suggest clinically meaningful impact on patient recovery from COVID-19 with an estimated 37 percent more recoveries observed in lenzilumab arm of Phase 3 trial versus current standard of care Data safety monitoring board recommendation demonstrates the Phase 3 trial is in the “promising zone” of the adaptive trial design
-
Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to Develop Lenzilumab for COVID-19
11/6/2020
The Cooperative Research and Development Agreement (CRADA) with the Department of Defense (DoD) in support of Operation Warp Speed (OWS) aims to improve the availability of lenzilumab for patients with COVID-19 Humanigen’s development efforts complemented by full-scale, integrated team of OWS leading experts and U.S. Government decision makers dedicated to advancing lenzilumab ahead of a potential Emergency Use Authorization (EUA) submission
-
There was a handful of positive clinical trial news reported today. Here’s a look.
-
Humanigen Announces ZUMA-19 Abstract Accepted for Presentation at American Society of Hematology 2020 Annual Meeting
11/4/2020
Humanigen, Inc. announced the acceptance of an abstract describing the ongoing ZUMA-19 study for presentation at the 62nd American Society of Hematology Annual Meeting & Exposition, to be held virtually from December 5-8, 2020.
-
Humanigen Executes Licensing Agreement for Lenzilumab™ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines
11/3/2020
Humanigen Executes Licensing Agreement for Lenzilumab ™ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines Agreement provides Humanigen up to US$20 million in milestones and double-digit royalties on product sales Transaction supports the Humanigen Asia-Pacific regional corporate development strategy BURLINGAME, Calif.--( BUSINESS WIRE )-- Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
-
Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19
10/30/2020
Humanigen, Inc. (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, today announced that MedStar Washington Hospital Center in Washington, D.C. treated its first COVID-19 patient with lenzilumab
-
Humanigen Announces First Patient Dosed in NIH ACTIV-5/Big Effect Trial Evaluating Lenzilumab™ for COVID-19
10/29/2020
First patient dosed at the Emory University School of Medicine in Atlanta, Georgia Trial will evaluate lenzilumab with remdesivir, compared to placebo and remdesivir, in up to 200 patients hospitalized with COVID-19 ’
-
National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy
10/13/2020
Lenzilumab among the promising agents selected for ACTIV program from pool of approximately 400 candidate agents